242 results on '"Brufsky, Adam M"'
Search Results
2. Supplementary Figure S1 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
3. Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
4. Supplementary Table from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
5. Data from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
6. Supplementary Figure S2 from Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
7. Organizational Breast Cancer Data Mart: A Solution for Assessing Outcomes of Imaging and Treatment
8. Biology of Coronaviruses and Predicted Origin of SARS-CoV-2
9. Ongoing Clinical Studies and Future Directions
10. Effects of aerobic exercise on neurocognitive function in postmenopausal women receiving endocrine therapy for breast cancer: The Exercise Program in Cancer and Cognition randomized controlled trial
11. Omission of surgery, primary endocrine therapy adherence, and effect of comorbidity in older women with estrogen receptor positive breast cancer
12. The Effect of Race and Area Deprivation on Symptom Profiles over the Course of Early-Stage Breast Cancer
13. Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer
14. Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
15. Erratum to Metaplastic Breast Carcinoma: A Clinical-Pathologic Study of 97 Cases With Subset Analysis of Response to Neoadjuvant Chemotherapy [Modern Pathology 32(6) (2019) 807–816]
16. Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer
17. Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
18. Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
19. Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
20. Data from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
21. Supplementary Figures 1-7 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
22. Supplementary Tables 1-15 from Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
23. Supplemental Table 1 from Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
24. Supplementary Table 1 from Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
25. Secondary Lymphedema Questionaire from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
26. Supplementary Figure 1 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
27. Supplementary Figure 1 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
28. Supplementary Figures 1-7 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
29. Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
30. Supplementary Figures 1-7 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
31. Supplementary Figure 2 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
32. Supplementary Figure 2 from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
33. Supplementary Table 1 from Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
34. Supplementary Data from Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs
35. Supplementary Tables 1-2 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
36. Supplementary Tables 1-2 from Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence
37. Secondary Lymphedema Questionaire from Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
38. Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
39. Abstract PD17-01: Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab (N+F+T)
40. Abstract P6-08-05: Racial and Economic Disparities in Social Support and Symptom Distress among Women Diagnosed with Early-Stage Breast Cancer
41. Abstract PD11-06: PD11-06 Circulating tumor DNA association with residual cancer burden after neoadjuvant therapy in triple negative breast cancer in TBCRC 030
42. Abstract OT2-01-07: evERA Breast Cancer: A phase III study of giredestrant (GDC-9545) + everolimus vs exemestane + everolimus in patients with estrogen receptor+, HER2– locally advanced or metastatic breast cancer
43. Abstract P4-07-09: Identifying Drivers of First-Line HR+/HER2- Metastatic Breast Cancer Treatment Choices
44. Abstract P4-02-20: Utility of the 70-gene signature and 10 year follow up in patients with early-stage breast cancer in a single institution study
45. Abstract PD9-08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database
46. Abstract P3-01-15: Real-world effectiveness of palbociclib plus aromatase inhibitors (AI) in African American (AA) patients with metastatic breast cancer (MBC)
47. Abstract OT2-16-05: Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Positive Metastatic Breast Cancer (MBC)
48. Abstract P3-01-14: Real-world treatment patterns of Palbociclib plus an aromatase inhibitor or aromatase inhibitor alone for metastatic breast cancer in the Flatiron database
49. Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)
50. Abstract P2-23-12: The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.